Aubrey Watson

Publications (2)7.53 Total impact

• Source

  Available from: alphavax.com

  Article: Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

  David I Bernstein, Elizabeth A Reap, Kevin Katen, Aubrey Watson, Kaitlin Smith, Pamela Norberg, Robert A Olmsted, Amy Hoeper, John Morris, Sarah Negri, Maureen F Maughan, Jeffrey D Chulay
  [show abstract] [hide abstract]
  ABSTRACT: Development of a cytomegalovirus (CMV) vaccine is a priority. We evaluated a two component alphavirus replicon particle vaccine expressing CMV gB or a pp65/IE1 fusion protein, previously shown to induce robust antibody and cellular immune responses in mice, in a randomized, double-blind Phase 1 clinical trial in CMV seronegative subjects. Forty subjects received a lower dose (LD) or higher dose (HD) of vaccine or placebo by intramuscular or subcutaneous injection at Weeks 0, 8 and 24. The vaccine was well tolerated, with mild to moderate local reactogenicity, minimal systemic reactogenicity, and no clinically important changes in laboratory parameters. All vaccine recipients developed ex vivo, direct IFN-gamma ELISPOT responses to CMV antigens (maximal mean spot-forming cells per 10(6) PBMC in LD and HD groups of 348 and 504 for pp65, 83 and 113 for IE1, and 138 and 114 for gB), and neutralizing antibodies (maximal geometric mean titer 110 with LD and 218 with HD). Polyfunctional CD4(+) and CD8(+) T cell responses were detected by polychromatic flow cytometry. This alphavirus replicon particle vaccine was safe and induced neutralizing antibody and multifunctional T cell responses against three CMV antigens that are important targets for protective immunity.
  Vaccine 10/2009; 28(2):484-93. · 3.77 Impact Factor
• Article: Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

  Bolyn Hubby, Todd Talarico, Maureen Maughan, Elizabeth A Reap, Peter Berglund, Kurt I Kamrud, Laura Copp, Whitney Lewis, Chad Cecil, Pamela Norberg, Jordan Wagner, Aubrey Watson, Sarah Negri, Bruce K Burnett, Andrew Graham, Jonathan F Smith, Jeffrey D Chulay
  [show abstract] [hide abstract]
  ABSTRACT: We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilot lots of HA VRP and NA VRP and clinical lots of HA VRP. HA VRP-induced high-titered antibody responses in mice, rabbits and rhesus macaques, as measured by ELISA or hemagglutination inhibition (HI) assays, and robust cellular immune responses in mice and rhesus macaques, as measured by IFN-gamma ELISPOT. NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza.
  Vaccine 12/2007; 25(48):8180-9. · 3.77 Impact Factor